<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642340</url>
  </required_header>
  <id_info>
    <org_study_id>ID-BSB-401</org_study_id>
    <nct_id>NCT03642340</nct_id>
  </id_info>
  <brief_title>A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo</brief_title>
  <official_title>A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a post-marketing surveillance of Besivo in participants with chronic hepatitis
      B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This post-marketing surveillance required by Korea MFDS regulation. The objectives of this
      study are to monitor adverse events and effectiveness of Besivo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 14, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse event after this drug administration in general medical practice.</measure>
    <time_frame>48weeks</time_frame>
    <description>Any adverse events occurred after this drug dosing will be recorded. Description of adverse event(s) including type of adverse event(s), onset/end date, severity, action taken, causal relationship to the drug and investigator's view on the adverse event(s) will be captured, whether it is related to the drug or not and until follow up visit more than 1 time during the surveillance period.
Lab abnormalities and changes in vital signs are considered to be adverse events only if they result in discontinuation from the study, necessitate therapeutic medical intervention, and/or if the investigator considers them to be adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse event after this drug administration in general medical practice.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Any serious adverse events occurred after this drug dosing will be recorded. Description of serious adverse event(s) including type of serious adverse event(s), onset/end date, severity, action taken, causal relationship to the drug and investigator's view on the serious adverse event(s) will be captured, whether it is related to the drug or not and until follow up visit more than 1 time during the surveillance period.
Lab abnormalities and changes in vital signs are considered to be adverse events only if they result in discontinuation from the study, necessitate therapeutic medical intervention, and/or if the investigator considers them to be adverse events.</description>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <eligibility>
    <study_pop>
      <textblock>
        3000
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient diagnosed with chronic hepatitis B.

          -  The patient who is first prescribed and administered Besivo.

        Exclusion Criteria:

          -  The patients who are overreacting to this drug or its components

          -  Medium to severe Renal function disorder

          -  The patient under 19

          -  The Patient who are taboo with L-Carnitine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ildong Ildong</last_name>
    <role>Study Director</role>
    <affiliation>PV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ildong Ildong</last_name>
    <phone>82-2-526-3295</phone>
    <email>eunbi@ildong.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ildong Ildong</last_name>
    <phone>82-2-526-3392</phone>
    <email>kimsh@ildong.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahn SangHoon</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

